Tags: Drug.

Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K an enzyme involved in bone resorption.It is being developed by Merck & Co.. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. It is expected Merck will apply for approval by mid-2013. J.P.

Odanacatib_Structural_Formulae_V.1.svg
ATC prefix
none
CAS number
603139-19-1
FDA UNII code
N673F6W2VH
IUPAC name
N-(1-cyanocyclopropyl)-4-fluoro-N2-(1S)-222-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl-(L)-leucinamide
PubChem
10152654

Loading...

This page contains content from the copyrighted Wikipedia article "Odanacatib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.